Natus Medical (NASDAQ:BABY) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, February 7th. Analysts expect the company to announce earnings of $0.70 per share for the quarter.
Natus Medical (BABY) opened at $31.45 on Wednesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.36 and a current ratio of 4.21. Natus Medical has a one year low of $28.05 and a one year high of $43.60. The company has a market capitalization of $979.80, a P/E ratio of -524.17 and a beta of 0.84.
BABY has been the subject of several research analyst reports. Zacks Investment Research upgraded Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 target price for the company in a research note on Tuesday, October 24th. Benchmark reiterated a “buy” rating and set a $49.00 target price (down from $55.00) on shares of Natus Medical in a research note on Tuesday, January 16th. William Blair downgraded Natus Medical from an “outperform” rating to a “market perform” rating in a research note on Monday, January 8th. Finally, BidaskClub cut Natus Medical from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $47.00.
In related news, Director William M. Moore sold 5,000 shares of Natus Medical stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $41.01, for a total transaction of $205,050.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Dong Chune Christopher Chung sold 12,642 shares of Natus Medical stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $42.91, for a total value of $542,468.22. Following the sale, the vice president now directly owns 141,414 shares of the company’s stock, valued at $6,068,074.74. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/31/natus-medical-baby-to-release-quarterly-earnings-on-wednesday.html.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.